Antibe Therapeutics Inc (CVE:ATE)’s share price shot up 12.5% on Thursday . The stock traded as high as C$0.27 and last traded at C$0.27. 295,160 shares changed hands during trading, a decline of 73% from the average session volume of 1,078,938 shares. The stock had previously closed at C$0.24.

The company has a debt-to-equity ratio of 24.97, a quick ratio of 2.60 and a current ratio of 4.26.

In other Antibe Therapeutics news, Director Walter Minnes Macnee bought 150,000 shares of the firm’s stock in a transaction dated Friday, September 28th. The stock was purchased at an average cost of C$0.34 per share, with a total value of C$51,000.00. Also, Director Michael Mcmillan bought 100,000 shares of the firm’s stock in a transaction dated Monday, September 24th. The shares were acquired at an average cost of C$0.31 per share, with a total value of C$31,000.00. Over the last 90 days, insiders have acquired 505,000 shares of company stock worth $152,200.

COPYRIGHT VIOLATION NOTICE: “Antibe Therapeutics (ATE) Shares Up 12.5%” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this story can be viewed at https://www.dailypolitical.com/2018/12/06/antibe-therapeutics-ate-shares-up-12-5.html.

Antibe Therapeutics Company Profile (CVE:ATE)

Antibe Therapeutics Inc, a pharmaceutical development company, originates, develops, and out-licenses patent protected pharmaceuticals in Canada, Europe, and the United States. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction, which has completed Phase IIB gastrointestinal safety study.

Further Reading: Dividend Aristocrat Index

Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.